Erzofri Extended-release Injection
NDC 72526-110
Product Information
Erzofri Extended-release (paliperidone palmitate) is a NDA-approved product labeled by Shandong Luye Pharmaceutical Co., Ltd.. This medication is used to treat certain mental/mood disorders (such as schizophrenia, schizoaffective disorder). It is supplied as a injection for intramuscular administration. This product entry covers the primary NDC 72526-110 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 72526-110?
What are the uses of this product?
What are Active Ingredients of this product?
- PALIPERIDONE PALMITATE 351 mg/2.25mL - A benzisoxazole derivative and active metabolite of RISPERIDONE that functions as a DOPAMINE D2 RECEPTOR ANTAGONIST and SEROTONIN 5-HT2 RECEPTOR ANTAGONIST. It is an ANTIPSYCHOTIC AGENT used in the treatment of SCHIZOPHRENIA.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- PALIPERIDONE PALMITATE (UNII: R8P8USM8FR)
- PALIPERIDONE (UNII: 838F01T721) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- CITRIC ACID MONOHYDRATE (UNII: 2968PHW8QP)
- POLYETHYLENE GLYCOL 4000 (UNII: 4R4HFI6D95)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- SODIUM PHOSPHATE, DIBASIC, ANHYDROUS (UNII: 22ADO53M6F)
- SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE (UNII: 593YOG76RN)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2699342 - paliperidone palmitate 351 MG in 2.25 ML Prefilled Syringe
- RxCUI: 2699342 - 2.25 ML paliperidone palmitate 156 MG/ML Prefilled Syringe
- RxCUI: 2699342 - paliperidone palmitate 351 MG per 2.25 ML Extended Release Injectable Suspension in a Prefilled Syringe
- RxCUI: 2699342 - paliperidone palmitate 351 MG per 2.25 ML Prefilled Syringe
- RxCUI: 2699348 - Erzofri 351 MG in 2.25 ML Prefilled Syringe
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.
Patient Education
Paliperidone Injection
Paliperidone extended-release injections are used to treat schizophrenia (a mental illness that causes disturbed or unusual thinking, loss of interest in life, and strong or inappropriate emotions) and schizoaffective disorder (a mental illness that causes both a loss of contact with reality and mood problems [depression or mania]). Paliperidone extended-release injection is in a class of medications called atypical antipsychotics. It works by changing the activity of certain natural substances in the brain.
[Learn More]
* Please review the full disclaimer at the bottom of this page.